Pfizer is shifting its strategy from large-scale acquisitions to internal artificial intelligence integration. The company completed a $43 billion acquisition of Seagen in 2023. Management plans to pause major M&A activity to mitigate rising costs and operational inefficiencies.
This strategic pivot aims to streamline operations and enhance internal processes. Pfizer intends for AI to drive growth as the company faces upcoming patent expirations on key drugs. The move addresses investor concerns regarding post-COVID growth drivers and looming patent cliffs.